TransCode Therapeutics Inc [NASDAQ: RNAZ] jumped around 0.09 points on Thursday, while shares priced at $0.40 at the close of the session, up 27.39%.
Compared to the average trading volume of 7.64M shares, RNAZ reached a trading volume of 10118891 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about TransCode Therapeutics Inc [RNAZ]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RNAZ shares is $10.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RNAZ stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
How has RNAZ stock performed recently?
TransCode Therapeutics Inc [RNAZ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.17. With this latest performance, RNAZ shares dropped by -42.30% in over the last four-week period, additionally sinking by -98.03% over the last 6 months – not to mention a drop of -97.36% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RNAZ stock in for the last two-week period is set at 32.13, with the RSI for the last a single of trading hit 39.16, and the three-weeks RSI is set at 33.67 for TransCode Therapeutics Inc [RNAZ]. The present Moving Average for the last 50 days of trading for this stock 2.3426, while it was recorded at 0.3195 for the last single week of trading, and 9.5592 for the last 200 days.
TransCode Therapeutics Inc [RNAZ]: Deeper insight into the fundamentals
TransCode Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.56 and a Current Ratio set at 2.56.
Earnings analysis for TransCode Therapeutics Inc [RNAZ]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RNAZ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for TransCode Therapeutics Inc go to 82.79%.
Insider trade positions for TransCode Therapeutics Inc [RNAZ]
There are presently around $0.71%, or 0.71%% of RNAZ stock, in the hands of institutional investors.
